Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection


Original post, click here
Experimental: Ipilimumab + Nivolumab

Participants receive Ipilimumab and Nivolumab.

Surgery performed after completion of induction therapy. Operative approach and extent of surgical resection based on the treating surgeon’s judgment.

Drug: Nivolumab

3 mg/kg by vein on Days 1, 15, and 29.

Other Names:

  • BMS-936558
  • Opdivo

Drug: Ipilimumab

1 mg/kg by vein on Day 1.

Other Names:

  • Yervoy
  • BMS-734016
  • MDX010

Procedure: Thoracic Surgery

Surgery performed after completion of induction therapy. Operative approach and extent of surgical resection based on the treating surgeon’s judgment.